L’Oréal has agreed to acquire a majority stake in Medik8, the British premium skincare brand, in a move that strengthens its Luxe Division’s portfolio and underscores continued private equity interest in the high-growth beauty segment.

Inflexion, the mid-market private equity firm that previously backed Medik8, will retain a minority stake under the terms of the transaction.

Founded by scientist Elliot Isaacs, Medik8 is known for its science-led formulations and “CSA Philosophy” – Vitamin C and sunscreen by day, Vitamin A by night. Its flagship product, Crystal Retinal, has gained cult status among skincare consumers. With a growing presence across Europe and the US, Medik8 has scaled through an omni-channel retail model and remains rooted in professional skincare innovation.

Inflexion will continue as a minority shareholder, with the brand’s founder and current management team remaining in place to support continuity and future growth. L’Oréal has also secured rights to buy out the remaining stake in the future.

“This is an exciting day for Medik8,” said CEO Simon Coble. “I am delighted to be joining forces with a company which shares our vision for the brand’s future growth and whose core values align with our deep commitment to science, innovation, and results without compromise.”

L’Oréal LUXE President Cyril Chapuy added, “Medik8 perfectly complements our skincare portfolio. We share a strong belief in its global potential and are excited to build a powerful brand presence worldwide.”

The deal is expected to close in the coming months, subject to regulatory approvals and customary conditions.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com. 

Can`t stop reading? Read more.